<DOC>
	<DOCNO>NCT01922037</DOCNO>
	<brief_summary>This multicenter , prospective study evaluate correlation participant 's characteristic , include biomarkers , predictive marker clinical outcome participant moderate severe asthma initiate treatment omalizumab . During 48 week , participant evaluate treated per investigator discretion follow study entry maximum follow-up 48 week , death , withdrawal consent , loss follow-up , study closure .</brief_summary>
	<brief_title>A Study Participants With Asthma Initiating Treatment With Omalizumab ( Xolair )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Participants identify investigator candidate treatment asthma omalizumab Confirmation access omalizumab insurance source funding Enrollment concurrent clinical trial Participants omalizumab treatment contraindicate Participants prior allergic reaction omalizumab excipients Participants treat omalizumab within previous year Participants receive experimental drug part another study within 3 month enrollment</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>